Shinichi Yachida
Johns Hopkins University
79 Papers
428 Citations
Shinichi Yachida is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Biology & Medicine. The author has an hindex of 25, co-authored 51 publications. Previous affiliations of Shinichi Yachida include Kagawa University.
Chat about Author
Papers
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Shinichi Yachida,Siân Jones,Ivana Bozic,Tibor Antal,Tibor Antal,Rebecca J. Leary,Baojin Fu,Mihoko Kamiyama,Ralph H. Hruban,James R. Eshleman,Martin A. Nowak,Victor E. Velculescu,Kenneth W. Kinzler,Bert Vogelstein,Christine A. Iacobuzio-Donahue +14 more
TL;DR: In this article, the authors rely on data generated by sequencing the genomes of seven pancreatic cancer metastases to evaluate the clonal relationships among primary and metastatic cancers and find that clonal populations that give rise to distant metastases are represented within the primary carcinoma, but these clones are genetically evolved from the original parental, non-metastatic clone.
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Peter J. Campbell,Peter J. Campbell,Shinichi Yachida,Laura Mudie,Philip J. Stephens,Erin Pleasance,Lucy Stebbings,Laura Morsberger,Calli Latimer,Stuart McLaren,Meng-Lay Lin,David J. McBride,Ignacio Varela,Serena Nik-Zainal,Catherine Leroy,Mingming Jia,Andrew Menzies,Adam Butler,Jon W. Teague,Constance A. Griffin,John Burton,Harold Swerdlow,Michael A. Quail,Michael R. Stratton,Michael R. Stratton,Christine A. Iacobuzio-Donahue,P. Andrew Futreal +26 more
TL;DR: It is found that pancreatic cancer acquires rearrangements indicative of telomere dysfunction and abnormal cell-cycle control, namely dysregulated G1-to-S-phase transition with intact G2–M checkpoint, and phylogenetic trees across metastases show organ-specific branches.
Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors
Shinichi Yachida,Efsevia Vakiani,Catherine M. White,Yi Zhong,Tyler Saunders,Richard A. Morgan,Roeland F. de Wilde,Anirban Maitra,Jessica Hicks,Angelo M. DeMarzo,Chanjuan Shi,Rajni Sharma,Daniel A. Laheru,Barish H. Edil,Christopher L. Wolfgang,Richard D. Schulick,Ralph H. Hruban,Laura H. Tang,David S. Klimstra,Christine A. Iacobuzio-Donahue,Christine A. Iacobuzio-Donahue +20 more
TL;DR: The finding of B cl-2 overexpression in poorly differentiated NECs, particularly small cell NEC, suggests that Bcl-2 antagonists/inhibitors may be a viable treatment option for these patients.
Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Minoru Oshima,Keiichi Okano,Shinobu Muraki,Reiji Haba,Takashi Maeba,Yasuyuki Suzuki,Shinichi Yachida +6 more
TL;DR: Genetic alterations of these 3 genes and their accumulation are strongly associated with malignant behavior of PDAC and may provide a new prognostic tool, assisting in deciding optimal therapeutic strategies for patients.
233
Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer
Erina Takai,Yasushi Totoki,Hiromi Nakamura,Chigusa Morizane,Satoshi Nara,Natsuko Hama,Masami Suzuki,Eisaku Furukawa,Mamoru Kato,Hideyuki Hayashi,Takashi Kohno,Hideki Ueno,Kazuaki Shimada,Takuji Okusaka,Hitoshi Nakagama,Tatsuhiro Shibata,Shinichi Yachida +16 more
TL;DR: Assessment of mutations and copy number alterations in plasma cfDNA may provide a prognostic and diagnostic tool to assist decisions regarding optimal therapeutic strategies for PDAC patients.